[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613282":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":38,"locations":44,"responsibleParty":64,"collaborators":29,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":29,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":29,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":47,"whyStopped":29,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"OA group","EXPERIMENTAL","petients received opioid-based anesthesia",[13],"Other: OA strategy",{"label":15,"type":10,"description":16,"interventionNames":17},"OSA group","patients received opioid-sparing anesthesia",[18],"Other: OSA stategy",{"label":20,"type":10,"description":21,"interventionNames":22},"OFA group","patients received opioid-free anesthesia",[23],"Other: OFA strategy",[25,30,34],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"OA strategy","For OA group, anesthesia induction was conducted with an intravenous targeted control infusion (TCI) of 3-4 μg\u002FmL propofol (effect-site concentration, Marsh mode), 2-3 ng\u002FmL remifentanil (effect-site concentration, Minto mode), 0.5 μg\u002Fkg sufentanil, and 0.6 mg\u002Fkg rocuronium. General anesthesia was maintained with a continuous TCI infusion of 3 to 4 μg\u002FmL propofol and 1 to 2 ng\u002FmL remifentanil, intermittently administrated sufentanil and rocuronium. Patient controlled intravenous analgesia (PCIA) was performed with 0.5μg\u002Fml of sufentanil and 0.75 mg\u002FmL flurbiprofen after surgery. The PCIA scheme was set with the continuous infusion rate of 4 ml\u002Fh and single bolus injection volume of 4ml. The locking time was 15 min, and the PCIA was stopped 48 h after surgery.",[9],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"OSA stategy","For OSA group, anesthesia induction was conducted with an intravenous targeted control infusion (TCI) of 3 to 4 μg\u002FmL propofol, 2 to 3 ng\u002FmL remifentanil, 0.3 μg\u002Fkg sufentanil, and 0.6 mg\u002Fkg rocuronium. After intubation, the patient received ultrasound-guided transversus abdominis plane (TAP) nerve block, with 0.375% ropivacaine 40mL injection. General anesthesia maintenance was consistent with OA group. Patient controlled intravenous analgesia (PCIA) was performed with 1mg\u002FmL of oxycodone and 0.75 mg\u002FmL flurbiprofen after surgery. The PCIA scheme was set with the continuous infusion rate was 4 ml\u002Fh and single bolus injection of 4ml. The locking time was 15 min, and the PCIA was stopped 48 hours after surgery.",[15],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"OFA strategy","For OFA group, before induction, an epidural catheter was inserted , and the catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of lidocaine 1% (3 ml) was injected through the catheter. Ropivacaine (0.25%) was maintained at a rate of 5 ml\u002Fh during surgery. Anesthesia induction was conducted with an intravenous targeted control infusion (TCI) of 3-4 μg\u002FmL propofol, 0.6 mg\u002Fkg rocuronium, 0.5mg\u002Fkg esketamine, 1mg\u002Fkg lidocaine and 0.5ug\u002Fkg dexmedetomidine. General anesthesia was maintained with a continuous TCI infusion of 3 to 4 μg\u002FmL propofol, 1.5-mg\u002Fkg\u002Fh continuous infusion of lidocaine, 0.25 mg\u002Fkg\u002Fh continuous infusion of esketamine. At the postoperative stage, the epidural administration regimen included 0.15% ropivacaine. The continuous infusion rate was 5ml\u002Fh, with an additional 5 ml upon the patient's request, and the locking time was 15 min. The epidural catheter was removed 48 hours after surgery.",[20],[39],{"name":40,"role":41,"phone":42,"phoneExt":29,"email":43},"Lingling Gao, MD","CONTACT","086-18818211563","LinglingGao@aliyun.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":62,"phoneExt":29,"email":63},"Jun Zhang, PhD","+86-21-64175590","snapzhang@aliyun.com",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Jun Zhang","Director, Head of Department of Anesthesiology,Principal Investigator, Clinical Professor","100613282","effect-of-ofa-osa-versus-opioid-based-anesthesia-on-nets-and-cancer-cell-malignancy-after-colorectal-cancer-surgery-100613282",false,"NCT07264556","Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery","Effect of Opioid-Free, Opioid-sparing Versus Opioid-based Anesthesia on Perioperative NETs and Cancer Cell Malignancy in Patients Undergoing Surgery for Colorectal Cancer: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* aged 18-80 years old,\n* American Society of Anesthesiologists physical status I-III,\n* elective colorectal cancer surgery under general anesthesia\n\nExclusion Criteria:\n\n* previous history of colorectal surgery,\n* addicted to opioids,\n* serious major mental or physical illness (heart, pulmonary, hepatic, or renal diseases),\n* radiotherapy or chemotherapy history within 8 weeks prior to the surgery,\n* contraindications to anesthetic agents or epidural.","ALL","18 Years","80 Years",{"count":79,"type":80},90,"ESTIMATED","INTERVENTIONAL",[83],"NA","Adult patients aged 18-80 years old, American Society of Anesthesiologists physical status I-III, who were scheduled for elective colorectal cancer surgery under general anesthesia were recruited for this study. They were randomized to receive opioid-free anesthesia (OFA), opioid-sparing anesthesia (OSA) and opioid-based anesthesia (OA) group.\n\nBlood samples were collected pre-surgery and 24h post-surgery. As primary endpoint, serum neutrophil myeloperoxidase (MPO) and citrullinated histone3 (CitH3) was measured. The secondary endpoints included the effects of postoperative serum on colorectal cancer (CRC) cells malignancy, numerical rating scale (NRS) scores, postoperative adverse events and recovery profiles.\n\nFor OA group, intraoperative remifentanil and sufentanil were used and postoperative patient controlled intravenous analgesia (PCIA) was performed with 0.5μg\u002Fml of sufentanil and 0.75 mg\u002FmL flurbiprofen, and the PCIA was stopped 48 h after surgery.\n\nFor OSA group, remifentanil and sufentanil were used only for anesthetic induction and the patient received ultrasound-guided transversus abdominis plane (TAP) nerve blockwas performed. Patient controlled intravenous analgesia (PCIA) was performed with 1mg\u002FmL of oxycodone and 0.75 mg\u002FmL flurbiprofen after surgery, and the PCIA was stopped 48 hours after surgery.\n\nFor OFA group, intraoperative epidural anesthesia combined with general anesthesia was used, and esketamine, lidocaine and dexmedetomidine for analgesia. Patient controlled epidural analgesia (PCEA) was used and terminated 48 hours after surgery.",[86,87,88],"Colorectal Cancer","Opioid-free Anesthesia","NETs",[90,91,92],"Opioid free anesthesia","Neutrophil extracellular trapping markers","colorectal cancer","2025-11-24",{"date":95,"type":96},"2025-12-04","ACTUAL",{"date":98,"type":96},"2025-11-01",{"date":100,"type":80},"2025-12-15",{"name":5,"class":6},1]